Pharmaceutical company Pfizer, which was accused for not revealing the side effects of its antidepressant drug Zoloft purposely to get more sales, was happy with the outcome of the initial U.S. trial on Friday. The drug was said to cause birth defects in children whose mothers took it during pregnancy. The case was filed by Kristyn Pesante who also said that the company was responsible for the risks of the medicine. Unfortunately, her son was born with a rare and serious congenital heart problem.
The trial was conducted in St. Louis, Missouri, and the conclusion was reached after a week. Pesante was asking the company for both settlement as well as disciplinary measure. Apart from the allegation of Pesante, a number of other lawsuits have also been filed against Zoloft owing to the fact that pregnant women gave birth to babies with cardiac as well as other abnormalities. The trial was an important one as it represented the voice of many expecting moms. Medical evidences and several possible theories were offered by Pfizer, neglecting the fact that there were various other instances throughout the nation.
Pesante filed the case in 2012 explaining that she took the medicine during her initial trimester as Pfizer claimed that Zoloft is the most effective treatment for expecting women experiencing depression. The company also claimed that it had the lowest risk of side effects as compared to other medicines serving the same purpose. She stated that she was not aware of its threats when she took the medication.
The company, however, presented evidences in its favor which explain that there is no direct link between Zoloft and birth defects in children. Additionally, clinical teams and agencies like the American Heart Association, American Psychiatric Association and also American College of Obstetricians and Gynecologists also support the company.
Zoloft has been approved by the U.S. Food and Drug Administration. The drug is also included in the group of antidepressant medicines called the Selective Serotonin Reuptake Inhibitors (SSRIs) which are commonly prescribed for reducing depression among ladies. Although Pfizer successfully scored a point during the first trial, Pesante and other mothers are still hopeful to make the company pay for their mistake in the next trial that will be held at Philadelphia’s state court later in this year.